Get the Stockscreener App
1.69
3.68%
0.06
After Hours:
1.72
0.03
+1.78%
Innate Pharma Adr stock is traded at $1.69, with a volume of 11,945.
It is up +3.68% in the last 24 hours and up +12.67% over the past month.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
See More
Previous Close:
$1.63
Open:
$1.73
24h Volume:
11,945
Relative Volume:
0.54
Market Cap:
$158.57M
Revenue:
$3.13M
Net Income/Loss:
$-55.77M
P/E Ratio:
-2.7502
EPS:
-0.6145
Net Cash Flow:
$-61.24M
1W Performance:
+16.55%
1M Performance:
+12.67%
6M Performance:
-19.91%
1Y Performance:
-11.52%
1-Day Range:
$1.64
$1.75
1-Week Range:
$1.38
$1.75
52-Week Range:
$1.17
$2.63
Innate Pharma Adr Stock (IPHA) Company Profile
Compare IPHA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
1.69 | 152.94M | 3.13M | -55.77M | -61.24M | -0.6145 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Sep-18-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-18-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-28-25 | Initiated | BTIG Research | Buy |
| Sep-03-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-15-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-24-20 | Initiated | Goldman | Neutral |
View All
Innate Pharma Adr Stock (IPHA) Latest News
Innate Pharma (IPHA) outlines oncology pipeline and key risks in Form 20-F - Stock Titan
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Sees Large Decline in Short Interest - MarketBeat
Innate Pharma Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management - Investing.com India
Innate Pharma reports 55% revenue drop, expects cash runway until end of Q3 2026 - Investing.com
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update - MarketBeat
Innate Pharma stock initiated with buy rating at BTIG on oncology pipeline By Investing.com - Investing.com India
Innate Pharma stock initiated with buy rating at BTIG on oncology pipeline - Investing.com
Innate Pharma (NASDAQ:IPHA) Shares Up 3.6%Here's What Happened - MarketBeat
Innate Pharma (NASDAQ:IPHA) Shares Up 3.6% – Here’s What Happened - Defense World
Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference - ChartMill
Innate Pharma (NASDAQ:IPHA) Stock Price Down 2.2%Should You Sell? - MarketBeat
Innate Pharma (NASDAQ:IPHA) Shares Down 0.5%Here's What Happened - MarketBeat
Innate Pharma (NASDAQ:IPHA) Shares Up 2.3% – Should You Buy? - Defense World
Innate Pharma (NASDAQ:IPHA) Shares Up 2.3%Should You Buy? - MarketBeat
Innate Pharma (NASDAQ:IPHA) Stock Price Up 3.7%Should You Buy? - MarketBeat
Earnings call transcript: Innate Pharma Q3 2025 shows innovation progress - Investing.com
Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances - Investing.com India
Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q3 2025 shows innovation progress By Investing.com - Investing.com UK
Disney, Brookfield, Nu Holdings and more set to report earnings Thursday - Investing.com UK
Pre Market Movers: SLRX, SI, ELDN Swing Big - RTTNews
Innate Pharma stock soars after FDA clears path for Phase 3 trial - Investing.com
Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - MSN
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer - GlobeNewswire Inc.
Should I buy Innate Pharma (IPHA) - Zacks Investment Research
Innate Pharma FY2025 EPS Forecast Increased by HC Wainwright - MarketBeat
Innate Pharma (NASDAQ:IPHA) Stock Price Down 3.9%Time to Sell? - MarketBeat
Lucid Capital Markets initiates coverage on Innate Pharma stock with Buy rating - Investing.com India
Goldman Sachs Sticks to Their Hold Rating for Innate Pharma SA (IPHYF) - Barchart.com
Leerink Partnrs Forecasts Innate Pharma Q3 Earnings - Defense World
Leerink Partners downgrades Innate Pharma stock on shift to ADC strategy - Investing.com
Earnings call transcript: Innate Pharma’s Q2 2025 focus on strategic assets - Investing.com
Innate Pharma stock initiated with Buy rating at BTIG on cancer therapy potential By Investing.com - Investing.com South Africa
TuHURA Biosciences (HURA) Short Interest & Short Float | Updated Jan 2026 - MarketBeat
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
What Are Earnings Reports? - MarketBeat
Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline - Investing.com
Earnings call: Innate Pharma reports progress in drug development - Investing.com
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Innate Pharma Announces Its Participation in Upcoming Investor Conference By Investing.com - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag - Nasdaq
What is the current Price Target and Forecast for Innate Pharma (IPHA) - Zacks Investment Research
Senti Biosciences (SNTI) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com
Annovis Bio (ANVS) Short Interest Ratio and Volume 2025 - MarketBeat
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - The Chronicle-Journal
BioAtla (BCAB) Short Interest & Short Float | Updated Jan 2026 - MarketBeat
Mersana Therapeutics (MRSN) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
Innate Pharma Adr Stock (IPHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):